Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of CXA-201 + metronidazole versus meropenem for complicated intra-abdominal infection
2011-002119-27Phase 3Completed
- Sponsor
- Cubist Pharmaceuticals, Inc.
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Intra-abdominal infection (IAI) comparing CXA-201 plus metronidazole with Meropenem (2 arms). Primary endpoint: Clinical cure rate at the TOC visit in the primary MITT population. Started Nov 2011; status: completed.
02
Drugs
ceftolozane + tazobactammetronidazolemeropenem
03
Conditions
Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on 2011-002119-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002119-27.